Bone Biologics Corporation  (BBLG)
Other Ticker:  


Bone Biologics Corporation

BBLG's Financial Statements and Analysis

Bone Biologics Corporation narrowed III. Quarter net loss per share of $-0.12 compare to net loss per share of $-0.17 recorded in the same quarter a year ago a decrease compare to $-0.05 realized in previous quarter.

III. Quarter
Earnings Per Share Revenues
$ -0.12 $  0 Mill
$+0.05     Unch.    

Bone Biologics's Revenue fell by 0 % in III. Quarter (Sep 30 2022) year on year, to $0 million and declined by sequentially.

Bone Biologics is Expected to report next financial results on March 14, 2023.

More on BBLG's Income Statement

Bone Biologics's in III. Quarter recorded net loss of $-1.219 million, an increase from net loss of $-0.509 million in III. Quarter a year ago.

Sequentially net loss advanced

More on BBLG's Growth

BBLG's Cash flow In III. Quarter company's net cash flow was $1 million

Bone Biologics Corporation does not pay out common stock dividend.

In trailing twelve-month period Bone Biologics Corporation payed $ -0.02 cash per share, on a free-cash flow basis .